Document is current
Any future updates will be listed below
-
Authors
Pratz, Keith W. https://orcid.org/0000-0002-1284-8266
Chai, Xinglei
Xie, Jipan
Yin, Lei
Nie, Xiaoyu
Montez, Melissa
Iantuono, Erica
Downs, Lisa
Ma, Esprit
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02993523 at ClinicalTrials.govDocuments that mention this clinical trial
New and emerging therapies for acute myeloid leukaemia
https://doi.org/10.1136/jim-2018-000807
Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet
https://doi.org/10.1007/s40261-022-01172-4
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective
https://doi.org/10.1007/s40273-022-01145-7
-
Funding
Funding for this research was provided by:
Genentech, Inc.
- License Information
-
More Information
Article History
Accepted: 7 April 2022
First Online: 13 June 2022
Declarations
:
: Support for this study was provided by Genentech, Inc.
: Keith W. Pratz is an associate professor of medicine at the Hospital of the University of Pennsylvania. Keith W. Pratz has received honoraria or consultancy fees from AbbVie, Astellas, Boston BioMedical, Jazz Pharmaceuticals, STI Pharmaceuticals, and Celgene; and institutional research funding from AbbVie, Astellas, Agios, and Millennium. Xinglei Chai, Jipan Xie, Lei Yin, and Xiaoyu Nie are employees of Analysis Group, Inc., which has received consulting fees from Genentech, Inc. Melissa Montez, Erica Iantuono, Lisa Downs, and Esprit Ma are employees of Genentech, Inc. and hold stock/options.
: This study is a post hoc analysis of previously collected data. No institutional board review was required.
: Not applicable.
: Not applicable.
: The research data are confidential and will not be shared.
: Code associated with this research will not be shared.
: Conceptualization: all authors; methodology: all authors; formal analysis and investigation: XC, JX, LY, and XN; writing—original draft preparation: XC, JX, LY, XN; writing—review and editing: all authors; funding acquisition: EM; resources: EM; supervision: EM. All authors approved the version of the submitted manuscript and agree to be accountable for all aspects of the work.
